Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) was the recipient of unusually large options trading activity on Wednesday. Traders purchased 6,450 put options on the stock. This is an increase of 3,331% compared to the typical daily volume of 188 put options.
In other Alnylam Pharmaceuticals news, Director Phillip A. Sharp sold 30,000 shares of the company’s stock in a transaction on Wednesday, November 25th. The shares were sold at an average price of $124.89, for a total value of $3,746,700.00. Following the transaction, the director now directly owns 265,633 shares in the company, valued at $33,174,905.37. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, COO Yvonne Greenstreet sold 3,125 shares of the company’s stock in a transaction on Tuesday, January 12th. The shares were sold at an average price of $161.00, for a total transaction of $503,125.00. Following the completion of the transaction, the chief operating officer now owns 7,945 shares in the company, valued at $1,279,145. The disclosure for this sale can be found here. Insiders have sold 63,066 shares of company stock worth $8,743,373 over the last ninety days. Insiders own 3.50% of the company’s stock.
A number of hedge funds and other institutional investors have recently modified their holdings of ALNY. Amundi Pioneer Asset Management Inc. increased its position in Alnylam Pharmaceuticals by 12.6% during the 1st quarter. Amundi Pioneer Asset Management Inc. now owns 149,659 shares of the biopharmaceutical company’s stock valued at $13,986,000 after purchasing an additional 16,733 shares during the period. American International Group Inc. increased its position in Alnylam Pharmaceuticals by 34.1% during the 2nd quarter. American International Group Inc. now owns 3,127 shares of the biopharmaceutical company’s stock valued at $463,000 after purchasing an additional 796 shares during the period. FMR LLC increased its position in Alnylam Pharmaceuticals by 1.6% during the 2nd quarter. FMR LLC now owns 17,074,631 shares of the biopharmaceutical company’s stock valued at $2,528,923,000 after purchasing an additional 269,322 shares during the period. First Republic Investment Management Inc. acquired a new stake in Alnylam Pharmaceuticals during the 2nd quarter valued at approximately $307,000. Finally, Advisor Group Holdings Inc. increased its position in Alnylam Pharmaceuticals by 16.2% during the 2nd quarter. Advisor Group Holdings Inc. now owns 1,684 shares of the biopharmaceutical company’s stock valued at $247,000 after purchasing an additional 235 shares during the period. Institutional investors and hedge funds own 92.35% of the company’s stock.
Alnylam Pharmaceuticals (NASDAQ:ALNY) last posted its earnings results on Tuesday, November 10th. The biopharmaceutical company reported ($2.18) EPS for the quarter, missing analysts’ consensus estimates of ($1.66) by ($0.52). The company had revenue of $125.85 million during the quarter, compared to the consensus estimate of $119.05 million. Alnylam Pharmaceuticals had a negative return on equity of 65.96% and a negative net margin of 222.19%. The firm’s revenue was up 79.6% compared to the same quarter last year. During the same period last year, the company posted ($1.50) EPS. Sell-side analysts forecast that Alnylam Pharmaceuticals will post -7.31 EPS for the current fiscal year.
Several research firms have commented on ALNY. Royal Bank of Canada decreased their price objective on shares of Alnylam Pharmaceuticals from $150.00 to $144.00 and set a “sector perform” rating on the stock in a report on Monday, December 21st. BidaskClub downgraded shares of Alnylam Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Wednesday, January 6th. Bank of America decreased their price target on shares of Alnylam Pharmaceuticals from $160.00 to $157.00 and set a “buy” rating on the stock in a research note on Thursday, October 15th. Morgan Stanley upped their price target on shares of Alnylam Pharmaceuticals from $200.00 to $203.00 and gave the company an “overweight” rating in a research note on Wednesday, November 25th. Finally, HC Wainwright restated a “buy” rating and issued a $225.00 price target on shares of Alnylam Pharmaceuticals in a research note on Friday, January 8th. Two analysts have rated the stock with a sell rating, six have given a hold rating and twelve have issued a buy rating to the company. Alnylam Pharmaceuticals presently has a consensus rating of “Buy” and a consensus price target of $159.06.
Alnylam Pharmaceuticals Company Profile
Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing RNA interference (RNAi) therapeutics. The company's pipeline of investigational RNAi therapeutics focus on genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and central nervous system/ocular diseases.
Recommended Story: Why is the conference call important?
Receive News & Ratings for Alnylam Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alnylam Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.